Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T19:45:30.805Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:45:30.805Z.

Quote observation: 2026-10-06T19:45:17.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 146,260,890
Total debt · period ending 2026-06-30: 31,569,000
Cash · period ending 2026-06-30: 59,443,000
TTM revenue · period ending 2026-06-30: 0

FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0

EV/EBITDA|P/S Ratio|Revenue|All Metrics

ABOS EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

EV/SALES RATIO AVG TTM

N/A

EV/SALES RATIO AVG 3Y

N/A

EV/SALES RATIO AVG 5Y

N/A

EV/SALES RATIO AVG 10Y

N/A

EV/SALES RATIO AVG 15Y

N/A

EV/SALES RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

ABOS Competitors' EV/Sales Ratio

ABOS

Acumen Pharmaceuticals, Inc.

Current

Market Cap

$146.26M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVXL

Anavex Life Sciences Corp.

vs ABOS

Market Cap

$145.96M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VYGR

Voyager Therapeutics, Inc.

vs ABOS

Market Cap

$146.82M

EV/Sales Ratio

4.17x

TTM Avg

6.09x

3Y Avg

3.52x

5Y Avg

3.55x

NGEN

NervGen Pharma Corp. Common stock

vs ABOS

Market Cap

$145.70M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TARA

Protara Therapeutics, Inc.

vs ABOS

Market Cap

$145.29M

EV/Sales Ratio

N/A

TTM Avg

74.21x

3Y Avg

74.21x

5Y Avg

74.21x

ALXO

ALX Oncology Holdings Inc.

vs ABOS

Market Cap

$147.35M

EV/Sales Ratio

N/A

TTM Avg

1521.81x

3Y Avg

1437.50x

5Y Avg

1437.50x

CDXS

Codexis, Inc.

vs ABOS

Market Cap

$147.36M

EV/Sales Ratio

2.48x

TTM Avg

3.21x

3Y Avg

3.47x

5Y Avg

4.66x

KRSA

Korsana Biosciences, Inc.

vs ABOS

Market Cap

$144.51M

EV/Sales Ratio

75.33x

TTM Avg

3.64x

3Y Avg

6.48x

5Y Avg

6.15x

FBIOP

Fortress Biotech, Inc.

vs ABOS

Market Cap

$144.06M

EV/Sales Ratio

0.18x

TTM Avg

6.51x

3Y Avg

3.60x

5Y Avg

2.98x

NYXH

Nyxoah S.A.

vs ABOS

Market Cap

$143.10M

EV/Sales Ratio

4.96x

TTM Avg

17.77x

3Y Avg

41.49x

5Y Avg

54.53x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Acumen Pharmaceuticals, Inc. (ABOS)	$146.26M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$145.96M	N/A	N/A	N/A	N/A
Voyager Therapeutics, Inc. (VYGR)vs ›	$146.82M	4.17x	6.09x	3.52x	3.55x
NervGen Pharma Corp. Common stock (NGEN)vs ›	$145.70M	N/A	N/A	N/A	N/A
Protara Therapeutics, Inc. (TARA)vs ›	$145.29M	N/A	74.21x	74.21x	74.21x
ALX Oncology Holdings Inc. (ALXO)vs ›	$147.35M	N/A	1521.81x	1437.50x	1437.50x
Codexis, Inc. (CDXS)vs ›	$147.36M	2.48x	3.21x	3.47x	4.66x
Korsana Biosciences, Inc. (KRSA)vs ›	$144.51M	75.33x	3.64x	6.48x	6.15x
Fortress Biotech, Inc. (FBIOP)vs ›	$144.06M	0.18x	6.51x	3.60x	2.98x
Nyxoah S.A. (NYXH)vs ›	$143.10M	4.96x	17.77x	41.49x	54.53x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

ABOS EV/Sales Ratio History

DATE	EV/SALES RATIO
2022-03-28	129.24x
2022-03-25	185.07x
2022-03-24	246.72x
2022-03-23	246.72x
2022-03-22	273.47x
2022-03-21	285.10x
2022-03-18	332.79x
2022-03-17	309.52x
2022-03-16	296.73x
2022-03-15	222.29x
2022-03-14	202.52x
2022-03-11	228.11x
2022-03-10	252.53x
2022-03-09	276.96x
2022-03-08	206.01x
2022-03-07	202.52x
2022-03-04	171.11x
2022-03-03	222.29x
2022-03-02	267.65x
2022-03-01	297.89x
2022-02-28	268.82x
2022-02-25	252.53x
2022-02-24	212.99x
2022-02-23	245.55x
2022-02-22	250.21x
2022-02-18	274.63x
2022-02-17	256.02x
2022-02-16	265.33x
2022-02-15	226.94x
2022-02-14	183.91x
2022-02-11	214.15x
2022-02-10	238.57x
2022-02-09	261.84x
2022-02-08	223.45x
2022-02-07	193.21x
2022-02-04	166.46x
2022-02-03	144.36x
2022-02-02	166.46x
2022-02-01	194.38x
2022-01-31	182.74x
2022-01-28	169.95x
2022-01-27	151.34x
2022-01-26	166.46x
2022-01-25	179.26x
2022-01-24	195.54x
2022-01-21	189.72x
2022-01-20	167.62x
2022-01-19	190.89x
2022-01-18	173.44x
2022-01-14	212.99x
2022-01-13	215.31x
2022-01-12	199.03x
2022-01-11	243.23x
2022-01-10	228.11x
2022-01-07	256.02x
2022-01-06	253.69x
2022-01-05	286.26x
2022-01-04	328.13x
2022-01-03	370.01x
2021-12-31	373.50x
2021-12-30	389.78x
2021-12-29	360.70x
2021-12-28	360.70x
2021-12-27	381.64x
2021-12-23	409.55x
2021-12-22	406.06x
2021-12-21	409.55x
2021-12-20	396.76x
2021-12-17	387.45x
2021-12-16	394.43x
2021-12-15	389.78x
2021-12-14	347.91x
2021-12-13	373.50x
2021-12-10	406.06x
2021-12-09	427.00x
2021-12-08	472.36x
2021-12-07	464.22x
2021-12-06	454.91x
2021-12-03	495.62x
2021-12-02	532.84x
2021-12-01	468.87x
2021-11-30	506.09x
2021-11-29	531.68x
2021-11-26	549.13x
2021-11-24	634.03x
2021-11-23	634.03x
2021-11-22	715.45x
2021-11-19	734.06x
2021-11-18	784.08x
2021-11-17	839.91x
2021-11-16	835.25x
2021-11-15	367.53x
2021-11-12	407.68x
2021-11-11	424.47x
2021-11-10	450.74x
2021-11-09	474.47x
2021-11-08	467.17x
2021-11-05	478.12x
2021-11-04	472.64x
2021-11-03	461.33x
2021-11-02	429.21x
2021-11-01	441.25x
2021-10-29	447.82x
2021-10-28	460.60x
2021-10-27	467.53x
2021-10-26	490.89x
2021-10-25	460.96x
2021-10-22	459.87x
2021-10-21	466.44x
2021-10-20	451.84x
2021-10-19	441.62x
2021-10-18	426.29x
2021-10-15	429.57x
2021-10-14	443.44x
2021-10-13	460.23x
2021-10-12	426.66x
2021-10-11	412.79x
2021-10-08	425.93x
2021-10-07	475.20x
2021-10-06	477.02x
2021-10-05	493.81x
2021-10-04	487.97x
2021-10-01	492.35x
2021-09-30	477.39x
2021-09-29	477.02x
2021-09-28	471.55x
2021-09-27	516.08x
2021-09-24	524.11x
2021-09-23	523.38x
2021-09-22	501.84x
2021-09-21	483.96x
2021-09-20	473.74x
2021-09-17	527.39x
2021-09-16	525.57x
2021-09-15	494.54x
2021-09-14	517.17x
2021-09-13	520.09x
2021-09-10	555.49x
2021-09-09	581.04x
2021-09-08	603.67x
2021-09-07	603.31x
2021-09-03	504.03x
2021-09-02	492.35x
2021-09-01	566.08x
2021-08-31	589.07x
2021-08-30	623.02x
2021-08-27	616.81x
2021-08-26	571.92x
2021-08-25	563.16x
2021-08-24	557.68x
2021-08-23	576.66x
2021-08-20	565.71x
2021-08-19	544.18x
2021-08-18	520.46x
2021-08-17	497.46x
2021-08-16	433.14x
2021-08-13	429.47x
2021-08-12	421.22x
2021-08-11	418.77x
2021-08-10	416.63x
2021-08-09	425.50x
2021-08-06	424.58x
2021-08-05	423.97x
2021-08-04	413.57x
2021-08-03	422.74x
2021-08-02	432.53x
2021-07-30	438.94x
2021-07-29	434.05x
2021-07-28	421.22x
2021-07-27	408.99x
2021-07-26	472.26x
2021-07-23	487.85x
2021-07-22	489.38x
2021-07-21	490.60x
2021-07-20	531.56x
2021-07-19	549.90x
2021-07-16	511.69x
2021-07-15	494.57x
2021-07-14	526.36x
2021-07-13	544.70x
2021-07-12	531.25x
2021-07-09	543.48x
2021-07-08	509.25x
2021-07-07	538.90x
2021-07-06	583.22x
2021-07-02	585.66x
2021-07-01	580.16x

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics

EV/Sales Ratio: N/A

ABOS EV/Sales Ratio Chart

ABOS EV/Sales Ratio Metrics

ABOS Competitors' EV/Sales Ratio

Understanding EV/Sales

EV/Sales Ratio Formula & Definition

ABOS EV/Sales Ratio History

Related Metrics